



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/051,164	10/10/2013	Juliana Megan WODA	ATY-0004US-DIV	9438
26294	7590	03/03/2020	EXAMINER	
TAROLLI, SUNDHEIM, COVELL & TUMMINO L.L.P. 1300 EAST NINTH STREET, SUITE 1700 CLEVELAND, OH 44114			PYLA, PAUL D	
			ART UNIT	PAPER NUMBER
			1653	
			NOTIFICATION DATE	DELIVERY MODE
			03/03/2020	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

docketing@tarolli.com
rkline@tarolli.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Ex parte JULIANA MEGAN WODA and WOUTER VAN'T HOF

Appeal 2019-004786
Application 14/051,164
Technology Center 1600

Before ERIC B. GRIMES, JOHN G. NEW, and JAMIE T. WISZ,
Administrative Patent Judges.

WISZ, *Administrative Patent Judge.*

DECISION ON APPEAL

STATEMENT OF THE CASE

Pursuant to 35 U.S.C. § 134(a), Appellant¹ appeals from the Examiner's decision to reject claims 23–30. We have jurisdiction under 35 U.S.C. § 6(b).

We AFFIRM.

CLAIMED SUBJECT MATTER

According to the instant Specification, “[t]he process of acute inflammation is initiated by the blood vessels local to the injured tissue, which alter to allow the exudation of plasma proteins and leukocytes into the surrounding tissue.” Spec. ¶ 2. The Specification describes the invention as being directed to “cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having a desired potency with respect to downregulating expression of cellular adhesion molecules in endothelial cells and reducing leukocyte adhesion and extravasation.” Spec. ¶ 1. Claim 23, the only independent claim, is illustrative of the claimed subject matter and is reproduced below:

23. A method to construct a cell bank, the method comprising expanding and storing cells (I), and further comprising detecting *in vitro* the effect of the cells (I) on (1) leukocyte extravasation, (2) leukocyte adhesion to vascular endothelium or to isolated endothelial cells, (3) cytokine-mediated activation of endothelial cells or (4) expression of one or more cell adhesion molecules on an endothelial cell by contacting cells (I) with a leukocyte and detecting the effect of the cells (I) on (1) or (2); or contacting cells (I) with an endothelial cell and detecting the effect of the cells (I) on (3) or (4), the cells (I)

¹ We use the word “Appellant” to refer to “applicant” as defined in 37 C.F.R. § 1.42. Appellant identifies the real party in interest as ABT Holding Company. Appeal Br. 3.

being non-embryonic, non-germ cells that have one or more of oct4 expression, telomerase expression, rex-1 expression, rox-1 expression or can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

Appeal Br. 19 (Claims App.).

REJECTIONS

The Examiner rejected claims 23–30 under 35 U.S.C. § 103(a) as being obvious over Maziarz² as evidenced by Korngold.³

The Examiner provisionally rejected claims 23–30 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 29–37 of co-pending Application No. 14/070,075.

The Examiner provisionally rejected claims 23–30 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 28–30 of co-pending Application No. 13/071,801 in view of Maziarz as evidenced by Korngold.

ISSUES AND ANALYSIS

Rejection of claims 23–30 under 35 U.S.C. § 103(a) as being obvious over Maziarz as evidenced by Korngold

The Examiner finds that Maziarz teaches a method of constructing a cell bank where the cells are expanded and stored. Final Act. 4 (citing Maziarz ¶¶ 43, 47, 200, 277, 337, 338, 340, and 384). The Examiner also

² Maziarz et al., US 2006/0263337 A1, published Nov. 23, 2006 (“Maziarz”).

³ Robert Korngold, et al., *Role of Tumor Necrosis Factor- α in Graft-versus-Host Disease and Graft-versus-Leukemia Responses*, *Biology of Blood and Marrow Transplantation* 9:292–303 (2003) (“Korngold”).

finds that Maziarz teaches that the expanded and stored cells are “multipotent adult progenitor cells” (MAPCs). *Id.* (citing Maziarz ¶¶ 40, 47). According to the Examiner, Maziarz teaches that the MAPCs have the limitations recited in claim 23 as shown in the chart below:

Claim 23 limitations of the cell:	Maziarz (paragraph(s)):
where the cells (i.e., “the” cells or “any” cells) are:	
non-embryonic and non-germ;	42, 168, 171 and 177
and cells that have one or more of:	
Oct4 expression	41, 59, 177, 178, claim 4;
Telomerase expression	41, 58, 177, 178, claim 3;
Rex-1 expression	41, 177, 333;
Rox-1 expression	41, 177, 333;
and cells can differentiate into cell types of at least two of	
endodermal,	39, 40, 177 191; Claims 1-2;
ectodermal and	39, 40, 177 191; Claims 1-2;
mesodermal germ layers	39, 40, 177 191; Claims 1-2;

Id. at 5. Overall, the Examiner finds that “Maziarz teaches the same cells (MAPCs) that express the same markers for the same purpose and uses the same expansion and storage methods as Applicant.” *Id.* at 4–5 (citing Maziarz ¶¶ 43, 47, 48, 49, 60, 213, 313, 317, 318, 337, 338, claims 5, 8–10; Spec. ¶¶ 98, 99).

With regard to the *in vitro* assay recited in the claims, the Examiner finds that the assay is not defined in the claims or the Specification such that it would provide any definitive meaning as to how the generic cell *in vitro* assay that detects the claimed effects is to be interpreted. Final Act. 2–3. Therefore, the claim terms are given their broadest reasonable interpretation, where detection “can be any physical wet lab assay known in the art that is able to assay any functional or physical properties of cells related to one of the four recited properties.” *Id.* at 3. The Examiner further finds that the claims encompass detection that can be a direct or an indirect effect (and are open to positive, negative, or neutral effect). Ans. 26, 31.

The Examiner finds that Example 6 of Maziarz teaches an assay in which ConA (a T-cell activator), responder T-cells (prepared from lymph nodes) and MAPCs were added to microtiter plate wells (e.g., MAPCs are in contact with lymphocytes-leukocytes). Final Act. 6 (citing Maziarz ¶¶ 405–409). The plates were incubated for 4–5 days, pulsed with ³H-thymidine, and then the cells were harvested and thymidine uptake was quantified in a micro-plate scintillation counter (i.e., detecting an effect of the cells on leukocytes). *Id.* (citing Maziarz ¶ 409). The results showed that MAPCs inhibited proliferation of ConA-activated T-cells and the amount of inhibition depended on the dose of MAPCs. *Id.* (citing Maziarz ¶ 412, Fig. 4).

Furthermore, according to the Examiner:

Maziarz teaches in regard to Example 7 that the addition of increasing doses of syngeneic Lewis MAPCs and non-matched (allogeneic) third-party Sprague-Dawley MAPCs resulted in a significant and dose-dependent inhibition of T-cell activation, where maximal levels of inhibition were ~80% and even at the lowest doses of MAPCs, there was 40-50% inhibition.

Ans. 30 (citing Maziarz ¶ 421).

The Examiner admits that Maziarz does not teach that MAPCs' suppression of proliferation of activated T-cells has an effect on leukocyte extravasation or adhesion to vascular endothelium; however, the Examiner finds that Korngold cures this deficiency. Final Act. 9. Specifically, the Examiner finds that Korngold provides evidence that when leukocytes are activated, they produce inflammatory cytokines, such as TNF- α , IFN- γ , and IL-2, and these inflammatory cytokines cause leukocyte extravasation and adhesion. *Id.* at 9–10 (citing Korngold 292–293). The Examiner further

finds that if MAPCs suppress activation of leukocytes, then they suppress production of these inflammatory cytokines and, therefore, MAPCs suppress leukocyte extravasation and adhesion. *Id.* at 10. The Examiner concludes that, “where Maziarz teaches an *in vitro* assay of observing [] the effect of MAPCs on leukocyte activation, that assay is inherently a detection of the effect of MAPCs on leukocyte extravasation or leukocyte adhesion to vascular endothelium.” *Id.*

The Examiner concludes that:

A person of ordinary skill in the art knows both Maziarz and Korngold and would look at the results from the Maziarz assays and even though Maziarz does not explicitly explain all the consequences that follow from the results, a person of ordinary skill in the art would have understood those consequential results since they would understand the pleiotropic functions of MAPCs, and from the evidence provided by Korngold that suppressing T-cell activation means that there is suppressed leukocyte extravasation. As noted above, the only thing that’s missing from Maziarz is the meaning of the results, and such meaning, in conjunction with the evidence provided by Korngold is inherent within Maziarz (MPEP § 2112 (II)).

Ans. 28–29.

Appellant does not appear to contest that the MAPCs disclosed in Maziarz meet the limitations of the “cells (I)” recited in the claims, nor that Maziarz teaches a method of constructing a cell bank by expanding and storing such cells as recited in the claims. Appellant’s main argument is that “the only conclusion that can be drawn from Maziarz is that MAPCs suppress T cell proliferation” and that “the mechanism underlying suppression of T cell proliferation is not inherently biologically linked” to leukocyte extravasation or adhesion “because the factors (e.g., cytokines,

signaling molecules and cellular components) involved in T cell proliferation and leukocyte extravasation are distinct.” Appeal Br. 11. Appellant also cites to the Declaration of Dr. Busch as support for this argument. *Id.* at 12 (“[T]here is no data provided by Maziarz that suggests identifying a factor (or factors) or a biological effect directly related to leukocyte extravasation, adhesion to vascular endothelium or to isolated endothelial cells...” Busch Decl. 3.))

Appellant further asserts that Maziarz fails to teach that MAPCs inherently affect T cell activation. Appeal Br. 13. Specifically, Appellant argues that, in the MLR (mixed lymphocyte reaction) assay described in Maziarz, responder T cells were stimulated with ConA and contacted with MAPCs to assess the effect of MAPCs on the *proliferation* of stimulated T cells but it is the presence of ConA in the MLR, and not the MAPCs, that affects T cell *activation* because ConA is a known T cell mitogen. *Id.* Appellant concludes that the Examiner incorrectly assumes that there is an inherent association between the ability of MAPCs to suppress T cell activation and leukocyte extravasation or adhesion because it is not the MAPCs that are affecting T cell activation. *Id.*

With regard to the statement in Example 7 of Maziarz that MAPCs inhibited T-cell activation, Appellant responds by contending that it is not clear what the term “T-cell activation” means in Maziarz and that the proper inquiry is how would the skilled artisan have interpreted this phrase at the time of the claimed invention. Reply 2. Appellant further asserts that the Declaration of Dr. Busch indicates that the skilled artisan would have only understood from Maziarz that MAPCs suppress T cell proliferation. Reply 2–3.

Appellant also asserts that Korngold does not remedy the deficiencies of Maziarz because it does not say anything about the action of MAPCs in inflammation. Appeal Br. 13.

We find that the Examiner has the better position. We begin with claim interpretation because before a claim is properly interpreted, its scope cannot be compared to the prior art. “[D]uring examination proceedings, claims are given their broadest reasonable interpretation consistent with the specification.” *In re Hyatt*, 211 F.3d 1367, 1372 (Fed. Cir. 2000). We agree with the Examiner that, under the broadest reasonable interpretation, the “detecting *in vitro*” limitation can be any physical or wet lab assay known in the art that is able to assay one of the four recited properties. We also agree that this limitation encompasses detection that is direct or indirect and can be positive, negative, or neutral. Therefore, the assays disclosed in Maziarz, which detect the effect of MAPCs on T-cell proliferation and/or activation, indirectly detect the effect of MAPCs on leukocyte extravasation and adhesion as evidenced by Korngold. *See* Korngold 292–293.

Appellant argues that the Declaration of Dr. Busch establishes that the skilled artisan would have understood from Maziarz only that MAPCs suppress T cell proliferation (Appeal Br. 11, Reply 2–3); however, we do not find this contention to be supported by the Busch Declaration. The Busch Declaration does not include such a broad statement nor does it specifically address the results of Example 7 from Maziarz, which found that addition of increasing doses of syngeneic Lewis MAPCs and non-matched (allogenic) MAPCs “resulted in a significant and dose-dependent inhibition of T-cell activation.” Maziarz ¶ 421 (emphasis added). As discussed in Korngold, T-cell activation leads to a cascade of cytokines, which ultimately leads to

leukocyte extravasation and leukocyte adhesion on vascular endothelium.
Korngold 292–293.

Furthermore, we agree with the Examiner that Maziarz teaches that MAPCs were known to have pleiotropic functions, not limited to a narrow subset of functions. *See, e.g.*, Maziarz ¶¶ 205–210. Therefore, by contacting MAPCs with a leukocyte, as disclosed in Maziarz (and as claimed), one is inherently detecting *in vitro* the effect of the cells on, e.g., leukocyte extravasation and/or leukocyte adhesion.

Therefore, we affirm the Examiner’s rejection of claim 23 as obvious over Maziarz in view of Korngold. Claims 24–30 are not argued separately apart from the independent claims, and, therefore, fall with claim 23. *See* 37 C.F.R. § 41.37(c)(1)(iv).

Provisional Obviousness-type Double Patenting of Claims 23–30

We decline to reach these undisputed provisional rejections. *See Ex parte Moncla*, Appeal No. 2009-006448 (PTAB June 22, 2010) (precedential) (holding that it is premature to address a provisional rejection).

CONCLUSION

For the reasons described herein and those already of record, we affirm the Examiner’s rejection of claims 23–30.

DECISION SUMMARY

In summary:

Claims Rejected	35 U.S.C. §	Reference(s)/Basis	Affirmed	Reversed
23–30	103	Maziarz, Korngold	23–30	
23–30		Provisional Obviousness-type Double Patenting ⁴		
23–30		Provisional Obviousness-type Double Patenting ⁵		
Overall Outcome			23–30	

TIME PERIOD FOR RESPONSE

No time period for taking any subsequent action in connection with this appeal may be extended under 37 C.F.R. § 1.136(a). *See* 37 C.F.R. § 1.136(a)(1)(iv).

AFFIRMED

⁴ As explained above, we do not reach this rejection per *Ex parte Moncla*, Appeal No. 2009-006448 (PTAB June 22, 2010) (holding that it is premature to address a provisional rejection) (designated precedential).

⁵ As explained above, we do not reach this rejection per *Ex parte Moncla*, Appeal No. 2009-006448 (PTAB June 22, 2010) (holding that it is premature to address a provisional rejection) (designated precedential).